Your browser is no longer supported. Please, upgrade your browser.
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E1680.78 EPS (ttm)0.08 Insider Own0.10% Shs Outstand223.30M Perf Week7.72%
Market Cap28.90B Forward P/E12.34 EPS next Y10.49 Insider Trans-2.55% Shs Float223.06M Perf Month15.86%
Income21.10M PEG94.28 EPS next Q2.18 Inst Own99.70% Short Float1.93% Perf Quarter9.20%
Sales4.13B P/S7.00 EPS this Y-95.70% Inst Trans2.65% Short Ratio2.42 Perf Half Y12.23%
Book/sh41.04 P/B3.15 EPS next Y12.86% ROA0.60% Target Price163.56 Perf Year5.05%
Cash/sh7.00 P/C18.48 EPS next 5Y17.83% ROE0.90% 52W Range92.56 - 140.77 Perf YTD32.93%
Dividend- P/FCF135.68 EPS past 5Y-40.60% ROI0.40% 52W High-8.06% Beta1.55
Dividend %- Quick Ratio2.50 Sales past 5Y21.60% Gross Margin90.90% 52W Low39.82% ATR3.42
Employees2656 Current Ratio2.90 Sales Q/Q24.00% Oper. Margin6.50% RSI (14)68.63 Volatility2.19% 2.71%
OptionableYes Debt/Eq0.35 EPS Q/Q-303.40% Profit Margin1.90% Rel Volume0.73 Prev Close125.93
ShortableYes LT Debt/Eq0.31 EarningsFeb 04 BMO Payout0.00% Avg Volume1.79M Price129.42
Recom1.80 SMA207.24% SMA5014.55% SMA2007.46% Volume1,295,557 Change2.77%
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-14-19 01:00PM  Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Zacks
Feb-13-19 01:00PM  Edited Transcript of ALXN earnings conference call or presentation 4-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
09:11AM  The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion Zacks
Feb-12-19 03:18PM  Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp Zacks
09:00AM  Alexion Announces Creation of New Roles on Executive Leadership Team Business Wire
Feb-11-19 08:39AM  Is Alexion (ALXN) a Great Growth Stock? Zacks
Feb-07-19 07:55AM  Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-06-19 09:50AM  Alexion Pharmaceuticals Inc (ALXN) Files 10-K for the Fiscal Year Ended on December 31, 2018
Feb-04-19 04:13PM  Biotech Reports Solid Fourth Quarter, But Slips On Mixed Guidance Investor's Business Daily
04:11PM  Stocks rise amid next batch of corporate earnings Yahoo Finance
02:46PM  Alexion Pharmaceuticals (ALXN) Q4 2018 Earnings Conference Call Transcript Motley Fool
12:45PM  Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
11:57AM  Stocks making the biggest moves midday: Papa John's, Sysco, Clorox & more CNBC
10:38AM  Economic & Earnings Data Deluge Zacks
10:26AM  Q4 Earnings Soldier on Gamely: GOOGL, CLX & More Zacks
08:54AM  Stocks Open Mixed, Dow Jones Drags Ahead Of Alphabet Earnings Investor's Business Daily
08:39AM  Here's Why Alexion Pharmaceuticals Gained 26.3% in January Motley Fool
08:30AM  Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates Zacks
07:48AM  Stocks making the biggest moves premarket: Papa John's, Spotify, Clorox, Yelp & more CNBC
06:52AM  Alexion: 4Q Earnings Snapshot Associated Press
06:33AM  Evolus Rises Midday as Botox Drama Unfolds
06:30AM  Alexion Reports Fourth Quarter and Full Year 2018 Results Business Wire
Feb-01-19 02:06PM  Why Amgen Should Buy Alexion Pharmaceuticals
06:30AM  Alexion to Highlight Rare Disease Portfolio at Investor Day Business Wire
Jan-31-19 07:26PM  Alexion (ALXN) to Report Q4 Earnings: What's in the Cards? Zacks
06:30AM  Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals GlobeNewswire
06:30AM  Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis Business Wire
Jan-29-19 11:10AM  Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Jan-28-19 10:01AM  Stock Market Tumbles On Caterpillar Earnings Miss, Nvidia Warning Investor's Business Daily
08:54AM  Stock Market Futures Extend Losses On Big Caterpillar Earnings Miss Investor's Business Daily
06:30AM  Alexion Announces Positive Top-Line Results from Phase 3 Study of ULTOMIRIS (Ravulizumab-cwvz) in Complement Inhibitor-Naïve Patients with atypical Hemolytic Uremic Syndrome (aHUS) Business Wire
Jan-25-19 07:55AM  Analysis: Positioning to Benefit within Cigna, Alexion Pharmaceuticals, Synchrony Financial, Global Medical REIT, Investors Real Estate Trust, and CPI Card Group Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-22-19 04:18PM  Biotech Stock Dips On $700 Million Risk After European Patent Vote Investor's Business Daily
Jan-18-19 09:00AM  Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019
Jan-11-19 10:59AM  Why Sarepta Therapeutics Stock Is Starting to Shine Again InvestorPlace
10:20AM  Estimating The Fair Value Of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Simply Wall St.
Jan-10-19 08:01AM  Three tech, three biotech companies that are top takeover targets in 2019 MarketWatch
Jan-08-19 01:23PM  Edited Transcript of ALXN earnings conference call or presentation 24-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
09:07AM  Why Alexion Pharmaceuticals Stock Fell 21% in December Motley Fool
08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-07-19 07:30AM  Alexion to Report Fourth Quarter and Full Year 2018 Results on Monday, February 4, 2019 Business Wire
Jan-02-19 04:30PM  Alexion to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-18 06:21PM  Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure Zacks
Dec-24-18 09:26AM  Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder Zacks
08:59AM  Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija Zacks
Dec-21-18 04:30PM  Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO Conference Business Wire -6.51%
04:25PM  'Santa Comes Early' As This Biotech Stock Grabs Its Fourth Approval Investor's Business Daily
11:23AM  Alexion Receives Early FDA Approval for ULTOMIRIS (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
10:50AM  U.S. FDA approves Alexion Pharma's rare blood disorder drug Reuters
10:27AM  U.S. FDA approves Alexion Pharma's blood disorder drug Reuters
09:19AM  Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead Zacks
08:49AM  Allakos (ALLK) Catches Eye: Stock Jumps 6.5% Zacks
Dec-20-18 06:48AM  Alexion Pharmaceuticals Enters Oversold Territory Zacks
Dec-19-18 09:12AM  Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint Zacks
Dec-18-18 05:32PM  Achillion Reports Positive Interim Data on Factor D Inhibitors Zacks
03:02PM  Why Achillion Pharmaceuticals Is Cratering Again Today Motley Fool
Dec-17-18 07:00AM  Report finds growing pains for rare disease drugs, but local biotechs buck trend American City Business Journals
Dec-14-18 12:02PM  Future HQ of Alexion, PTC sells for $455M to Norges Bank, American Realty American City Business Journals
10:25AM  AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals Zacks
Dec-12-18 03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
08:52AM  Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher Zacks
Dec-10-18 08:45AM  Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher Zacks
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
05:05AM  Should You Avoid Alexion Pharmaceuticals, Inc. (ALXN)? Insider Monkey
Dec-05-18 09:49AM  Inovio (INO) to Receive Milestone Payment From AstraZeneca Zacks
08:46AM  UNITY (UBX) Soars: Stock Adds 5.1% in Session Zacks
08:41AM  Should You Get Rid of Acadia Healthcare (ACHC) Now? Zacks
Dec-04-18 04:34PM  Amgen's BiTE Immunotherapies Show Promise in Early Studies Zacks
08:13AM  Global Blood Therapeutics' Voxelotor on Faster Approval Path Zacks
Dec-03-18 02:32PM  Comprehensive Positive Phase 3 Data for Alexions ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood Business Wire
09:41AM  FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate Zacks
08:44AM  Fate Therapeutics (FATE) Jumps: Stock Rises 8.9% Zacks
Nov-30-18 08:39AM  Why Immunomedics (IMMU) Could Be Positioned for a Slump Zacks
Nov-28-18 10:22AM  Aileron Inks Collaboration Deal With Pfizer for Cancer Combo Zacks
Nov-27-18 10:44AM  Eyenovia Initiates Phase III Study for Mydriasis Candidate Zacks
08:37AM  Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher Zacks
Nov-26-18 02:40PM  Should You Be Worried About Alexion Pharmaceuticals Incs (NASDAQ:ALXN) 1.7% Return On Equity? Simply Wall St.
08:44AM  Keryx (KERX) Looks Good: Stock Adds 7.2% in Session Zacks
Nov-21-18 03:20PM  Health Care Stocks Help This Fund Offset Tech Stocks' Dive Investor's Business Daily
Nov-20-18 04:30PM  Alexion to Present at the Evercore ISI Healthcare Conference Business Wire
04:25PM  IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses Investor's Business Daily
09:10AM  Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint Zacks
08:37AM  Fortress Biotech (FBIO) in Focus: Stock Moves 6.5% Higher Zacks
Nov-19-18 09:43AM  Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension Zacks
08:41AM  Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session Zacks
Nov-15-18 08:31AM  Looking for a Growth Stock? Why It is Time to Focus on Alexion Pharmaceuticals (ALXN) Zacks
Nov-12-18 10:50AM  AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark Zacks
Nov-08-18 11:11AM  Alexion Pharmaceuticals Dropped 19.4% in October, but the Business Remains Strong Motley Fool
Nov-07-18 04:30PM  Alexion to Present at Credit Suisses 27th Annual Healthcare Conference Business Wire
Nov-06-18 09:30AM  Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year? Zacks
Nov-02-18 11:05AM  Alexion Completes Acquisition of Syntimmune Business Wire
08:15AM  Report: Developing Opportunities within General Electric, Arch Capital Group, China Petroleum & Chemical, Alexion Pharmaceuticals, GAIN Capital, and Sony Future Expectations, Projections Moving into 2018 GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Alexion Pharmaceuticals and OncoSec Medical ACCESSWIRE
Nov-01-18 03:34PM  Biotech ETFs in Focus on String of Q3 Earnings Beat Zacks +6.81%
10:23AM  Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting Business Wire
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
05:19AM  Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-24-18 11:28PM  Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript Motley Fool -9.76%
04:41PM  Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue Investor's Business Daily
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases; and strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain (AL) amyloidosis. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HANTSON LUDWIGCEODec 31Sale95.853,244310,937150,696Jan 03 06:07 PM
Franchini Indrani LallEVP, Chief Compliance OfficerNov 28Sale118.132,605307,72929,304Nov 30 06:15 PM
Clancy Paul JEVP, Chief Financial OfficerJul 10Sale131.115,241687,14893,309Jul 12 05:23 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale118.531,466173,76531,909Jun 12 04:52 PM
Goff BrianEVP & Chief Commercial OfficerJun 08Sale118.531,645194,98236,257Jun 12 04:51 PM
LAW ANNE-MARIEEVP and CHROJun 08Sale118.531,862220,70329,450Jun 12 04:51 PM
ORLOFF JOHN JEVP, Research & DevelopmentJun 08Sale118.532,115250,69131,790Jun 12 04:51 PM
COUGHLIN CHRISTOPHER JDirectorApr 30Buy120.7910,0001,207,90026,333May 02 05:42 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale118.6145453,84949,140Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale118.6168681,36642,787Mar 01 05:25 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale120.7224429,45649,594Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale120.72939113,35643,473Mar 01 05:25 PM